Our Programmes

At LEO Pharma we are passionate about improving people’s lives. We listen to the needs of patients and healthcare professionals and aim through our programmes to drive awareness, deliver high quality education and develop innovative solutions together that will make a real, tangible difference to care and patient outcomes.

 

 

Dermatology

Grounded in a desire to succeed in our global mission to help people achieve healthy skin, we have been at the forefront of dermatological care for over half a century through our approach and developing pioneering treatments and resources. Here are some examples of our programmes:

Helping SARAH is our ethical and people-focused ethos that runs through the core of our organisation. It brings a personal perspective, a name to all of the people living with the conditions we aim to treat in the centre of all we do. We continually challenge ourselves by asking: “How is this Helping SARAH?”

The Voices in Partnership (ViP) programme brings together people living with the conditions that we tackle so that we can better understand the day-to-day impact of having a dermatological (skin) or thrombotic condition (blood clot), allowing us to work together to drive change.

QualityCare™ is a free and confidential service to support people living with psoriasis or Cancer Associated Thrombosis (CAT). Illustrating LEO Pharma’s commitment to support the community beyond treatment, QualityCare™ provides relevant and credible information including treatment options and disease management through holistic and multichannel support. As well as diet and nutrition advice, QualityCare™ includes The Blogger Universe, which houses real stories from real people living with psoriasis and MindBoost, a stress management and mindfulness tool developed in collaboration with expert consultants in dealing with stress. A psoriasis app – MyPso – is also available on the App Store and Google Play.

Thrombosis

Striking statistics such as that each year around 4,000 people in England die from Cancer Associated Thrombosis (CAT)1 and that VTE is the second most common cause of death in patients with cancer2,  are the reason that we strive to deliver and support access to effective thrombotic (blood) treatments and resources as well as to raise awareness of the importance of education on Cancer Associated Thrombosis (CAT).

CAThrombosis is an award-winning web portal for healthcare professionals that contains extensive educational and news content on the area of blood clots in cancer. The resource aims to provide a stimulating suite of educational resources for healthcare professionals who wish to educate themselves further in this complex double-sided clinical relationship between malignancy and thrombosis.

 

 

Blood Clots, Cancer and You is another award winning programme, developed in partnership with AntiCoagulation Europe (ACE), which raises awareness of the risks of blood clots in cancer patients. Together we developed innovative resources to provide much needed information to healthcare professionals who provide counsel and care and patients who may be at risk.

 

 

References:
1APPTG Venous Thromboembolism (VTE) In Cancer Patients Oct 16, page 5
2APPTG Venous Thromboembolism (VTE) In Cancer Patients Oct 16, page 6

Cookies on this site

LEO Laboratories Limited uses cookies to give you the best experience online and to provide anonymised, aggregated site usage data. You can find out what cookies we use, what they do and how you can disable them in our Cookie Policy. By browsing our sites, you consent to the use of cookies. If you want to know more about our cookie policy and how to avoid and delete cookies click here. By continuing to browse this site, you consent to our use of cookies on this device in accordance with our cookie policy unless you have disabled them.